Screening and early detection of prostate cancer: PSA and beyond

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** F. Abdollah, Detroit (US)  
F.C. Hamdy, Oxford (GB)  
M.J. Roobol, Rotterdam (NL)

**Aims and objectives of this session**
The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

---

234

An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial

**By:** Johnston T. 1, Lamb A. 1, Vowler S. 2, Xiong T. 1, Moore A. 1, Holding P. 3, Herbert P. 1, Davis M. 4, Lane A. 4, Donovan J. 4, Hamdy F. 5, Neal D. 1

**Institutes:** University of Cambridge, Academic Urology Group, Cambridge, United Kingdom,  
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom,  
University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom,  
University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom,  
University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

235

At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study

**By:** Carlsson S. 1, Arnsrud Godtman R. 2, Holmberg E. 3, Lilja H. 4, Månsson M. 2, Stranne J. 2, Hugosson J. 2

**Institutes:** Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America,  
Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden,  
Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden,  
Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden

236

Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

**By:** Margel D. 1, Mano R. 1, Benjaminov O. 2, Kedar I. 3, Ozalvo R. 1, Sela S. 1, Ber Y. 1, Daniel J. 1

**Institutes:** Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel,  
Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel,  
Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel

237

Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1.0 ng/ml) worthwhile?

**By:** Urata S., Kitagawa Y., Mizokami A.

**Institutes:** Kanazawa University, Dept. of Urology, Kanazawa, Japan

238

The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database

**By:** Gild P. 1, Von Landenberg N. 1, Cole A. 1, Jiang W. 2, Lipsitz S. 2, Learm P. 3, Sun M. 1, Choueiri T. 4, Nguyen P. 4, Chun F. 5, Fisch M. 6, Kibel A. 1, Menon M. 1, Sammon J. 7, Koehlmoos T. 8, Haider A. 2, Trinh Q-D. 1

**Institutes:** Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery
and Center For Surgery and Public Health, Boston, United States of America, 2Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, United States of America, 3Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, 4Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Boston, United States of America, 5Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikutti Urology Institute, Detroit, United States of America, 8Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America

239

**Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml?**

By: Callerot P.1, Moineau M-P.2, Cussenot I.3, Baschet F.3, L'Her J.1, Doucet L.1, Cancel-Tassin G.3, Cormier L.4, Mangin P.3, Cussenot O.5, Fournier G.1, Valeri A.1

Institutes: 1Brest University Hospital, Dept. of Urology, Brest, France, 2Brest University Hospital, Nuclear Medicine Laboratory, Brest, France, 3Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, 4Dijon University Hospital, Dept. of Urology, Dijon, France, 5Tenon University Hospital, Dept. of Urology, Paris, France

240

**Risk of prostate-cancer death at 20 years stratified by midlife PSA and a panel of four kallikrein markers from a representative cohort of 11,506 healthy unscreened men aged 45-74**

By: Sjoberg D.D.1, Vickers A.J.2, Assel M.2, Dahlin A2, Carlsson S.1, Poon B.Y.3, Ulmert D.1, Lilja H.G.1

Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, 3Lund University, Clinical Microbiology, Malmo, Sweden

241

**Inclusion of mpMRI into the European Randomized study of Screening for Prostate Cancer (ERSPC) risk calculator: A new proposal to improve the accuracy of prostate cancer detection**

By: Dell'Oglio P.1, Stabile A.1, Gandaglia G.1, Brembilla G.2, Maga T.1, Cristel G.2, Kinzikeeva E.1, Losa A.1, Esposito A.2, Cardone G.2, De Cobelli F.2, Del Maschio A.2, Gaboardi F.1, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy

242

**Head-to-head comparison of commonly used international prostate cancer risk calculators for prostate biopsy**

By: Pereira-Azevedo N.1, Verbeek J.1, Nieboer D.2, Steyerberg E.2, Roobol M.1

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands

243

**Outcomes of PSA-based prostate cancer screening among men using non-steroidal anti-inflammatory drugs**

By: Murtola T.1, Vettenranta A.2, Talala K.3, Taari K.4, Stenman U.-H.6, Tammela T.1, Auvinen A.6

Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, 4Helsinki University, School of Medicine, Helsinki, Finland, 5Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, 6University of Tampere, School of Health Sciences, Tampere, Finland

244

**Decreasing screening efficacy with increasing age: Results from a population-based screening trial - Swiss ERSPC (Aarau)**

By: Praise L.1, Wyler S.1, Möltgen T.1, Huber A.2, Grobholz R.2, Manka L.4, Recker F.1, Kwiatkowski M.1

Institutes: 1Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, 2Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, 3Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, 4Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany
Stage distribution of prostate cancer at a tertiary care oncology centre in India - reflections of an unscreened population
By: Prakash G.¹, Bakshi G.¹, Shinde R.², Bhamre R.², Murthy V.³, Rent E.⁴, Pal M.¹, Mahantshetty U.³, Menon S.⁵
Institutes: ¹Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, ²Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, ³Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, ⁴AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, ⁵Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India

The diverse genomic landscape of low-risk prostate cancer
By: Cooperberg M.¹, Erho N.², Chan J.³, Feng F.³, Cowan J.³, Simko J.³, Ong K.², Alshalalfa M.³, Kolisnik T.², Margrave J.², Aranes M.², Du Plessis M.², Buerki C.⁴, Zhao S.², Tenggara I.³, Davicioni E.², Carroll P.³
Institutes: ¹University of California, Dept. of Urology, San Francisco, United States of America, ²GenomeDx, San Diego, United States of America, ³UCSF, Dept. of Urology, San Francisco, United States of America, ⁴GenomeDx, , San Diego, United States of America

A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)
By: Arsov C.¹, Becker N.², Herkommer K.³, Gschwend J.³, Imkamp F.⁴, Kuczyk M.⁴, Hadaschik B.⁵, Hohenfellner M.⁵, Siener R.⁶, Kristiansen G.⁷, Antoch G.⁸, Albers P.¹
Institutes: ¹University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, ³Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, ⁴Hanover Medical School, Dept. of Urology, Hanover, Germany, ⁵University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ⁶University of Bonn, Dept. of Urology, Bonn, Germany, ⁷University of Bonn, Dept. of Pathology, Bonn, Germany, ⁸University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany